|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | New York State Psychiatric Institute |
|---|---|
| Information provided by: | New York State Psychiatric Institute |
| ClinicalTrials.gov Identifier: | NCT00296712 |
Purpose
Relatively drug naive patients will receive two antidepressant medications as initial treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Major Depression Dysthymia Depression NOS |
Drug: Escitalopram Drug: Bupropion |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
| Official Title: | Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication. |
| Enrollment: | 55 |
| Study Start Date: | February 2005 |
| Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
While antidepressant medications are often effective in relieving depressive symptoms, at least 60% of patients do not remit with the first agent tried. This pilot study will assess whether giving two standard medications simultaneously (i.e., Escitalopram and Bupropion) is both tolerated and improves response while decreasing drop outs. This is a replication of a previous study.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, New York | |
| Depression Evaluation Service - New York State Psychiatric Institute | |
| New York, New York, United States, 10032 | |
| Principal Investigator: | Jonathan W. Stewart, MD. | New York State Psychiatric Institute - Columbia University Department of Psychiatry |
More Information
| Responsible Party: | New York State Psychiatric Institute ( Jonathon W. Stewart, M.D. ) |
| Study ID Numbers: | IRB4653 |
| Study First Received: | February 24, 2006 |
| Last Updated: | January 14, 2008 |
| ClinicalTrials.gov Identifier: | NCT00296712 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Major Depression Dysthymia Depression NOS Escitalopram |
Bupropion Dual Therapy Combination Therapy |
|
Dopamine Uptake Inhibitors Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Depressive Disorder, Major Cholinergic Agents Mental Disorders Therapeutic Uses Dexetimide |
Antidepressive Agents, Second-Generation Antidepressive Agents Depression Depressive Disorder Serotonin Uptake Inhibitors Citalopram Pharmacologic Actions Behavioral Symptoms Muscarinic Antagonists Serotonin Agents Autonomic Agents Bupropion Mood Disorders Dopamine Agents Dysthymic Disorder |